Recent Release – Global Recombinant Coagulation Factors Market, Share, Size, Dynamic Research, Expert Opinion, Forecasts Report 2017 – Acute Market Reports

A Technology & Pipeline Assessment and Corporate Benchmarking Analysis


The report “Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: Technology & Pipeline Assessment and Corporate Benchmarking Analysis” of June 2013 describes a market forecast based on growth of historical sales of recombinant coagulation factors. The report evaluates reasons for failures of novel recombinant coagulation factors and provides detailed profiles of active recombinant coagulation factors in clinical development. Preclinical projects are valued on the basis of the underlying technologies. Emerging alternative therapeutic approaches are described and assessed. The detailed target pipeline assessments put emphasis on the competitive situation regarding stage of development, inhibitor profile, half-life, administration frequency, clinical success and especially time to approval/market. The pipelines of the clinically active companies are described and their competitive position assessed in light of the key success factors. Sources of information are LMP’s proprietary database, scientific literature (abstracts, papers), corporate information (press releases, presentations, reports, SEC filings). All information is referenced.

Browse Full Report Visit –

Combined product sales of the three classes olf recombinant coagulation factors used in hemophilia were US$ 7.172 mln in 2012. The pipeline of new recombinant coagulation factors is maturing and the first molecules are under regulatory review by the FDA and the EMA and many have entered pivotal clinical studies. There are 46 different molecules and R&D approaches for novel recombinant coagulation factors for hemophilia A and B in the pipeline of which 24 are in clinical development of under regulatory review. Given this tight competition, time-to-market will be an important success. This report will explain the potential development and approval timelines of each of the advanced molecules.


What will you find in this report?

  • Historical sales data of the recombinant coagulation factors VIII, IX, VIIa and II;
  • Historical growth rates and a 5-year sales forecast of each class of recombinant factors;
  • Reasons for failure and profiles of failed recombinant coagulation factors;
  • Detailed profiles of clinical stage recombinant coagulation factors;
  • Technologies used for creation of novel recombinant coagulation factors;
  • Preclinical stage recombinant coagulation factors;
  • New approaches: alternative procoagulants / adjuncts and gene therapy;
  • Pipeline analysis and assessment for each recombinant coagulation factor class;
  • Comparative data on clinical inhibitor formation and discussion of its relevance;
  • Comparison of half-life prolongation and its impact on administration frequency;
  • Comparison of the time to approval for each clinical stage recombinant coagulation factor;
  • Company pipeline and competitive position of each major player in the field

Browse All Reports of This Category –

1 Executive Summary

2 Recombinant Coagulation Factor Markets

2.1 Recombinant Factor VIII (rFVIII) Market

2.1.1 rFVIII Product Sales

2.1.2 rFVIII Market Dynamic

2.2 Recombinant Factor IX (rFIX) Product Sales and Market Dynamics

2.3 Recombinant Factor VII (rFVII) Product Sales and Market Dynamics

2.4 Market Size & Dynamics of Recombinant Coagulation Factors in Hemophilia

2.5 Total Recombinant Coagulation Factors Market

3 Pipeline Changes & Drug Profiles

3.1 Discontinued Development of Recombinant Coagulation Factors

3.1.1 BAY 86-6150

3.1.2 Vatreptacog alfa; NN1731; NNC 0078-0000-0007; rFVIIa-DVQ

3.1.3 N7-GP; NN7128 (SC) / NN7129 (IV); NNC 0128-0000-2011; LA-rFVIIa

3.1.4 BAX 499; ARC19499

3.2 Active Clinical Development of Recombinant Coagulation Factors

3.2.1 Recombinant factor XIII

3.2.2 Recombinant von Willebrand factor

3.2.3 Wild-type and Biosimilar Recombinant Factor VIII

3.2.4 Long-acting Recombinant factor VIII

3.2.5 Wild-type and Biosimilar Recombinant Factor IX

3.2.6 Long-acting Recombinant Factor IX

3.2.7 Wild-type Recombinant factor VIIa

3.2.8 Long-acting Recombinant factor VIIa

4 Comparative Target Pipeline Analysis & Assessment

4.1 Recombinant Factor VIII Pipeline

4.1.1 Clinical Pipeline of Novel Recombinant Factor VIII Molecules

4.1.2 Preclinical Pipeline of Novel Recombinant Factor VIII Molecules

4.2 Recombinant Factor IX Pipeline

4.3 Recombinant Factor VII Pipeline

4.4 Recombinant Fibrinogen and Thrombin Pipeline

4.5 Recombinant von Willebrand Factor Pipeline

4.6 Recombinant Factor XIII

4.7 Alternative Procoagulants & Adjuncts Pipeline

4.8 Gene Therapy of Hemophilia

5 Corporate Benchmark Analysis

5.1 Stakeholder Overview

5.2 Stakeholders per Company


Bayer HealthCare Pharmaceuticals

Biogen Idec


Chugai (Roche)


About – Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.

Contact Us :

Name : Chris Paul


Designation : Global Sales Manager

Toll Free(US/CANADA): +1-855-455-8662

Email :

Website :

Designed by
Powered by
%d bloggers like this: